EA201791675A1 - Человеческие антитела к гликопротеину вируса эбола - Google Patents
Человеческие антитела к гликопротеину вируса эболаInfo
- Publication number
- EA201791675A1 EA201791675A1 EA201791675A EA201791675A EA201791675A1 EA 201791675 A1 EA201791675 A1 EA 201791675A1 EA 201791675 A EA201791675 A EA 201791675A EA 201791675 A EA201791675 A EA 201791675A EA 201791675 A1 EA201791675 A1 EA 201791675A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- virus
- present
- ebola virus
- globoprotein
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 4
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к моноклональным антителам или их антигенсвязывающим фрагментам, которые связываются с гликопротеинами вируса Эбола, фармацевтическим композициям, содержащим указанные антитела, и способам их применения. Антитела по настоящему изобретению пригодны для ингибирования или нейтрализации активности вируса Эбола, таким образом обеспечивая средство для лечения или предупреждения развития у людей инфекции, вызываемой вирусом Эбола. В соответствии с некоторыми вариантами осуществления настоящее изобретение относится к применению одного или нескольких антител, которые связываются с вирусом Эбола, для предупреждения прикрепления вируса к клеткам-хозяевам и/или его проникновения в них. Антитела по настоящему изобретению можно применять профилактически или терапевтически и можно применять отдельно или в комбинации с одним или несколькими другими противовирусными средствами или вакцинами.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562107581P | 2015-01-26 | 2015-01-26 | |
US201562161356P | 2015-05-14 | 2015-05-14 | |
US201562245703P | 2015-10-23 | 2015-10-23 | |
PCT/US2016/014720 WO2016123019A1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791675A1 true EA201791675A1 (ru) | 2017-12-29 |
EA038993B1 EA038993B1 (ru) | 2021-11-18 |
Family
ID=55300806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791675A EA038993B1 (ru) | 2015-01-26 | 2016-01-25 | Человеческие антитела к гликопротеину вируса эбола |
Country Status (20)
Country | Link |
---|---|
US (5) | US9771414B2 (ru) |
EP (1) | EP3250591A1 (ru) |
JP (3) | JP6829199B2 (ru) |
KR (1) | KR102641731B1 (ru) |
CN (2) | CN113354732B (ru) |
AU (2) | AU2016211783B2 (ru) |
BR (1) | BR112017015845A2 (ru) |
CA (1) | CA2974899A1 (ru) |
CL (3) | CL2017001920A1 (ru) |
CO (1) | CO2017007619A2 (ru) |
EA (1) | EA038993B1 (ru) |
IL (1) | IL253358B (ru) |
MA (1) | MA41421A (ru) |
MX (2) | MX2017009716A (ru) |
MY (3) | MY196224A (ru) |
PH (1) | PH12017501277A1 (ru) |
SG (2) | SG11201705681YA (ru) |
TW (1) | TWI710573B (ru) |
UY (1) | UY36538A (ru) |
WO (1) | WO2016123019A1 (ru) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
WO2018017964A2 (en) * | 2016-07-21 | 2018-01-25 | Emory University | Ebola virus antibodies and binding agents derived therefrom |
KR102369014B1 (ko) | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
WO2018081203A1 (en) | 2016-10-25 | 2018-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
CN108570106B (zh) * | 2017-03-10 | 2021-07-16 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
CN110914293B (zh) | 2017-07-06 | 2024-08-13 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
WO2019139648A2 (en) * | 2017-09-15 | 2019-07-18 | David Weiner | Dna antibody constructs for use against ebola virus |
WO2019060062A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
AU2018392334A1 (en) | 2017-12-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
EP3724223A1 (en) * | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019152607A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against ebola virus |
WO2019152303A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharmaceuticals, Inc. | Systems and methods for characterizing drug product impurities |
TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
AU2019227531A1 (en) | 2018-02-28 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
WO2019182901A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
EA202092281A1 (ru) * | 2018-03-26 | 2021-01-22 | Ридженерон Фармасьютикалз, Инк. | АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
AU2019299321A1 (en) | 2018-07-02 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture |
US11939370B2 (en) | 2018-07-12 | 2024-03-26 | Vanderbilt University | Pan-ebola virus neutralizing human antibodies and methods of use therefor |
CN112218877A (zh) | 2018-08-27 | 2021-01-12 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
CN111138526B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
SG11202104237YA (en) | 2019-01-16 | 2021-05-28 | Regeneron Pharma | Methods for identifying free thiols in proteins |
US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
WO2020231992A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Gspエンタープライズ | 抗ヒトCripto−1抗体 |
CN114760986A (zh) | 2019-11-25 | 2022-07-15 | 里珍纳龙药品有限公司 | 使用非水性乳液的持续释放调配物 |
GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
BR122023021668A2 (pt) | 2020-01-21 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Método para determinar a estabilidade de uma proteína de interesse |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
EP4093435A1 (en) * | 2020-01-24 | 2022-11-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
WO2022074630A1 (en) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Liquid oral suspension of favipiravir |
AU2021385363A1 (en) | 2020-11-25 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
US20220404369A1 (en) | 2021-03-03 | 2022-12-22 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
MX2023014246A (es) | 2021-06-01 | 2024-01-17 | Regeneron Pharma | Ensayos y reactivos de microchips de electroforesis capilar. |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
AU2022360838A1 (en) | 2021-10-07 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
EP4413359A1 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
AU2023208050A1 (en) | 2022-01-14 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630144B1 (en) | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
EP3048115B1 (en) * | 2008-02-01 | 2019-05-01 | Her Majesty The Queen In Right of Canada as represented by The Minister of Health | Monoclonal antibodies for ebola and marburg viruses |
EP2350270B1 (en) | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
US20170183396A1 (en) | 2014-02-19 | 2017-06-29 | Jody Berry | Ebola monoclonal antibodies |
CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
WO2015200522A2 (en) | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
SG10201902924RA (en) | 2014-10-03 | 2019-05-30 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
WO2016061504A2 (en) | 2014-10-17 | 2016-04-21 | The University Of Chicago | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein |
TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA041421A patent/MA41421A/fr unknown
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active IP Right Grant
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/en active Application Filing
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 MX MX2017009716A patent/MX2017009716A/es unknown
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-25 CA CA2974899A patent/CA2974899A1/en active Pending
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 EP EP16703030.3A patent/EP3250591A1/en active Pending
- 2016-01-25 BR BR112017015845A patent/BR112017015845A2/pt active Search and Examination
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-12 PH PH12017501277A patent/PH12017501277A1/en unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP2020120683A/ja active Pending
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201691877A1 (ru) | Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома | |
EA201591973A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201592203A1 (ru) | Способы лечения таупатии | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 | |
PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
EA202191973A2 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
EA201991135A1 (ru) | Комбинированная терапия ингибиторами аргиназы | |
AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
EA202090453A3 (ru) | Антитела к cd40 |